drugset / Trial / NCT03025893
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
RandomizedParallel-groupOpen-labelTreatment
Summary
In this study the investigators will evaluate the effect of high-dose, intermittent sunitinib versus treatment with lomustine in patients with recurrent glioblastoma multiforme. The investigators hypothesize that sunitinib, when given in a high-dose, intermittent schedule, will achieve adequate concentration levels in the tumor and will, besides its anti-angiogenic properties, inhibit gliomagenesis by inhibition of multiple kinases.
Timeline
- Start
- 2018-08-31
- Primary completion
- 2022-01-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lomustine | Small molecule | 110 mg/m2 | Oral |
| Subject | Sunitinib | Small molecule | 300 mg | Oral |
| Subject | Sunitinib | Small molecule | 700 mg | Oral |